We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
206 result(s) found, displaying 51 to 60
-
Prescription medicine decision summaryLivtencity (maribavir) is approved to treat cytomegalovirus (CMV).
-
Prescription medicine registrationActive ingredients: maribavir.
-
Designation or determinationOrphan drug
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Prescription medicine decision summaryTGA decision: Exkivity (mobocertinib) is approved to treat lung cancer
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Mesalazine 1.2 TAKEDA (mesalazine) 1.2 g prolonged release tablet blister pack.
-
Prescription medicine registrationActive ingredients: mobocertinib succinate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TAKHZYRO lanadelumab (rch) 300 mg/2 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENTYVIO vedolizumab 108 mg/0.68 mL solution for injection pre-filled pen.